business / news / / Devdiscourse
Powder supplement brand AG1 is exploring a sale option involving the whole company.
C4 Therapeutics and Roche signed a $1 billion deal for degrader-antibody conjugate cancer drugs.
KEY POINTS
- The C4-Roche partnership targets undisclosed oncology indications under exclusive agreement terms.
- AG1, also known as Athletic Greens, is considering a full or partial sale valued over $2 billion.
- Granules India will digitize documentation and tighten oversight after an FDA warning for manufacturing violations.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →